Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients?

Schizophrenia Bulletin

Volumn 28, Issue 2, 2002, Pages 193-201

  Storosum, Jitschak G ^a,b   Elferink, André J A ^f   Van Zwieten, Barbara J ^f   Van Strik, Roel ^c   Hoogendijk, Witte J G ^d   Broekmans, André W ^c,e  

^a Med Evauation Board of Netherlands   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f NONE

Author keywords

Amisulpride; Methodology; Negative symptoms; Placebo

Indexed keywords

AMISULPRIDE; PLACEBO; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HOSPITALIZATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; QUESTIONNAIRES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0036458393     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006931     Document Type: Article

References (57)

1. Andreasen, N. Scale for the Assessment of Negative Symptoms. Iowa City, IA: University of Iowa, 1984a.
2. Andreasen, N. Scale for the Assessment of Positive Symptoms. Iowa City, IA: University of Iowa, 1984b.
3. American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed. Washington, DC: APA, 1980.
4. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed., Revised. Washington, DC: APA, 1987.
5. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: APA, 1994.
6. Arvanitis, L.A.; Miller, B.G.; and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quefiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry, 42:233-246, 1997.
7. Beasley, C.M., Jr.; Sanger, T.; Satterlee, W.; Tollefson, G.; Tran, P.; Hamilton, S.; and Olanzapine HGAP Study Group. Olanzapine versus placebo: Results of a double-blind, fixed dose olanzapine trial. Psychopharmacology, 124:159-167, 1996a.
8. Beasley, C.M., Jr.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T.; Hamilton, S.; and Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14:111-123, 1996b.
9. Borison, R.L.; Arvanitis, L.A.; Miller, B.G.; and the USA Seroquel Study Group. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology. 16:158-169, 1996.
10. Borison, R.L.; Pathiraja, A.P.; Diamand, B.I.; and Meibach, R.C. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin. 28:213-218, 1992.
11. Boyer, P.; Lecrubier, Y.; Puech, J.; Dewailly, J.; and Aubin, F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry, 166:68-72, 1995.
12. Buchanan, R.W.; Breier, A.; Kirkpatrick, B.; Ball, P.; and Carpenter, W.T., Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry, 155:751-760, 1998.
13. Carpenter, W.T., Jr.; Heinrichs, D.W.; and Alphs, L.D. Treatment of negative symptoms. Schizophrenia Bulletin, 11(3):440-452, 1985.
14. Carpenter, W.T., Jr.; Heinrichs, D.W.; and Wagman, A.M.I. Deficit and nondeficit forms of schizophrenia: The concept. American Journal of Psychiatry, 145:578-583, 1988.
15. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; and Beauclar, L.A. Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993.
16. Committee on Proprietary Medicinal Products. Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. CPMP/EWP/559/95. http://www2.eudra.org/humandocs/humans/EWP.htm, 1998.
17. Conley, R.; Gounaris, C.; and Tamminga, C. Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biology Psychiatry, 35:746-747, 1994.
18. Crow, T.J. The two-syndrome concept: Origins and current status. Schizophrenia Bulletin, 11(3):471-486, 1985.
19. Danion, J-M.; Rein, W.; Fleurot, O.F.; and the Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. American Journal of Psychiatry, 156:610-616, 1999.
20. Delcker, A.; Schoon, M.L.; Oczkowski, B.; and Gaertner, H.J. Amisulpride versus haloperidol in treatment of schizophrenic patients - Results of a double-blind study. Pharmacopsychiatry, 23:125-130, 1990.
21. Farde, L.; Nordstrom, A-L.; Wiesel; F-A.; Pauli, S.; Halldin, C.; and Sedvall; G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry, 49:538-544, 1992.
22. Feighner, J.P.; Robins, E.; Guze, S.B.; Woodruff, R.A., Jr.; Winokur, G.; and Munoz, R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26:57-63, 1972.
23. Goff, D.C.; Tsai, G.; Levitt, J.; Amico, E.; Manoach, D.; Schoenfeld, D.A.; Hayden, D.L.; McCarley, R.; and Coyle, J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56:21-27, 1999.
24. Goldberg, S.C. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin, 11(3):453-456, 1985.
25. Greden, J.F., and Tandon, R., eds. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC: American Psychiatric Press, 1991.
26. Harvey, P.D., and Keefe, R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158:176-184, 2001.
27. Kane, J.; Honigfeld, G.; Singer, J.; and Melzer, H. Clozapine for the treatment-resistant schizophrenics: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
28. Kay, S.R., and Opler, L.A. The positive-negative dimension in schizophrenia: Its validity and significance. Psychiatric Developments, 2:79-103, 1987.
29. Keck, P., Jr.; Buffenstein, A.; Ferguson, J.; Feighner, J.; Jaffe, W.; Harrigan, E.P.; and Morrissey, M.R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology, 140:173-184, 1998.
30. King, D.J.; Link, C.G.G.; and Kowalcyk, B.A. Comparison of bid and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology, 137:139-146, 1998.
31. Kirkpatrick, B.; Buchanan, R.W.; McKennedy, P.D.; Alphs, L.D.; and Carpenter, W.T., Jr. The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia. Psychiatry Research, 30:119-123, 1989.
32. Kirkpatrick, B.; Kopelowicz, A.; Buchanan, R.W.; and Carpenter, W.T., Jr. Assessing the efficacy of treatment for the deficit syndrome of schizophrenia. Neuropsycho-pharmacology, 22:303-310, 2000.
33. Kopelowicz, A.; Zarate, R.; Tripodis, K.; Gonzales, V.; and Mintz, J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. American Journal of Psychiatry, 157:987-993, 2000.
34. Kraepelin, E. Dementia Praecox and Paraphrenia. (1919) Translated by R.M. Barclay. Huntington, NY: Robert E. Krieger, 1971.
35. Loo, H.; Poirier-Littre, M-F.; Théron, M.; Rein, W.; and Fleurot, O. Amisulpride versus placebo in the medium-term treatment of negative symptoms of schizophrenia. British Journal of Psychiatry, 170:18-22, 1997.
36. Marder, S.R., and Meibach, R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
37. Meltzer, H.Y.; Sommers, A.A.; and Luchins, D.J. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. Journal of Clinical Psychopharmacology, 6:329-338, 1986.
38. Möller, H-J. Neuroleptic treatment of negative symptoms in schizophrenic patients: Efficacy problems and methodological difficulties. European Neuropsychopharmacology, 3:1-11, 1993.
39. Möller, H-J.; Boyer, P.; Fleurot, O.; Rein, W.; and PROD-ASLP Study Group. Improvement of acute exacerbation of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacology, 132:396-401, 1997.
40. Möller, H-J.; van Praag, H.M.; Aufdembrinke, B.; Baily, B.; Barnes, T.R.; Beck, J.; Bentsen, H.; Eich, F.X.; Farrow, L.; Fleischhacker, W.W.; Gelach, J.; Grafford, K.; Hentschel, B.; Hertkorn, A.; Heylen, S.; Lecrubier, Y.; Leonard, J.P.; McKenna, P.; Maier, W.; Pederson, V.; Rappard, A.; Rein, W.; Ryan, J.; Sloth Nielsen, M.; Stieglitz, R-D.; Wegener, G.; and Wilson, J. Negative symptoms in schizophrenia: Considerations for clinical trials. Working Group on Negative Symptoms in Schizophrenia. Psychopharmacology, 115:221-228, 1994.
41. Paillère-Martinot, M-L.; Lecrubier, Y.; Martinot, J-L.; and Aubin, F.A. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. American Journal of Psychiatry, 152:130-133, 1995.
42. Perrault, G.; Depoortere, R.; Morel, E.; Sanger, D.J.; and Scatton, B. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3, dopamine receptor antagonist activity and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics, 280:73-82, 1997.
43. Peuskens, J., and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multi-center, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166:712-726, 1995.
44. Peuskens, J.; Bech, P.; Möller, H-J.; Bale, H.J.; Fleurot, O.; and Rein, W. Amisulpride vs. risperidone in the treatment of acute exacerbation of schizophrenia. Amisulpride Study Group. Psychiatry Research, 88:107-117, 1999.
45. Puech, A.J.; Fleurot, O.; Rein, W.; and the Amisulpride Study Group. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol. Acta Psychiatrica Scandinavica, 98:65-72, 1998.
46. Rosenheck, R.; Dunn, L.; Peszke, M.; Cramer, J.; Xu, W.; Thomas, J.; and Chamey, D. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. American Journal of Psychiatry, 156:88-93, 1999.
47. Scatton, B.; Claustre, Y.; Cudennec, A.; Oblin, A.; Perrault, G.; Snager, D.J.; and Schoemaker, H. Amisulpride: From animal pharmacology to therapeutic action. International Clinical Psychopharmacology, 12(Suppl 2):S29-S36, 1997.
48. Schneider, K. Clinical Psychopathology. (1950) Translated by M.W. Hamilton. New York, NY: Grune and Stratton, 1959.
49. Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquir, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; and Scatton, B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics, 280:83-97, 1997.
50. Small, J.G.; Hirsch, S.R.; Aravantis, L.A.; Miller, B.G.; Link, C.G.G.; and the Seroquel Study Group. Quetiapine in patients with schizophrenia. Archives of General Psychiatry, 54:549-557, 1997.
51. Spitzer, R.L.; Endicott, J.E.; and Robins, E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders. 3rd Ed. New York, NY: New York State Psychiatric Institute, Biometric Research Group of Functional Disorders, 1977.
52. Storosum, J.G.; Elferink, A.J.A.; and van Zwieten, B.J. Schizophrenia: Do we really need placebo-controlled studies? European Neuropsychopharmacology, 8:279-286, 1998.
53. Strauss, J.S.; Carpenter, W.T.; and Bartko, J.J. The diagnosis and understanding of schizophrenia: III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia Bulletin, 11:61-69, 1974.
54. Temple, R., and Ellenberg, S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments: I. Ethical and scientific issues. Annals of Internal Medicine, 133:455-463, 2000.
55. Tollefson, G.D.; Beasley, C.M., Jr.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A.; and Thiem, M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154:457-465, 1997.
56. Wetzel, H.; Gründer, G.; Hillert, A.; Philipp, M.; Gattaz, W.F.; Sauer, H.; Adler, G.; Schröder, J.; Rein, W.; Benkert, O.; and the Amisulpride Study Group. Amisulpride versus flupentixol in schizophrenia with predominant positive symptomatology-a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. Psychopharmacology, 137:223-232, 1998.
57. Zimbroff, D.L.; Kane, J.M.; Tamminga, C.A.; Daniel, D.G.; Mack, R.J.; Wozniak, P.J.; Sebree, T.B.; Wallin, B.A.; Kashkin, M.D.; and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154:782-791, 1997.